Current filters:  
Canada
Food and Drugs Law
Canada
Gowling WLG
In Canada, claims to new uses based on the discovery of "hitherto unrecognized properties" constitute patentable subject matter
Bennett Jones LLP
Growing investment in technology (AgTech) and innovation, Environment, Sustainability and Governance (ESG)...
Smart & Biggar
CIHI: On December 17, the Canadian Institute for Health Information (CIHI) published statistics on drug spending, finding that in 2018, around 40% of drug spending was...
Smart & Biggar
In November 2019, we highlighted the key proposed amendments to Regulations made under the Ontario Drug Benefit Act (ODBA) and the Drug Interchangeability and...
Smart & Biggar
On November 20, 2019, the Federal Court (FC) issued its reconsideration decision on the quantum of damages owed by Apotex for its infringement of eight Eli Lilly process...
Miller Thomson LLP
In an unprecedented move, Alberta Health Services and Alberta Health decided to conduct a complete review of the way in which health care delivered by Alberta Health Services is regulated, governed and funded.
Fasken
The Patented Medicine Prices Review Board recently published draft Guidelines to replace the current Compendium of Policies, Guidelines and Procedures, leading up to the coming into force of the amended ...
Fasken
In preparation for the coming into force of the amended Patented Medicines Regulations, the PMPRB has published draft guidelines to replace the current Compendium of Policies, Guidelines and Procedures.
Bereskin & Parr LLP
Biotechnology companies have a long road to commercialization. Investors, shareholders and company officials often have their patience tested
Osler, Hoskin & Harcourt LLP
When patents expire on a patented drug product, paving the way for generic competition, the patentee is faced with the challenge of how to replace the revenues that were achieved...
Norton Rose Fulbright Canada LLP
The Canadian pharma and life sciences space saw many developments in 2019. These included major policy initiatives and regulatory changes affecting the industry, driven in part by three high-profile
Smart & Biggar
In 2019, Rx IP Update reported on a number of developments in Canadian life sciences IP and regulatory law. We review top developments below:...
McCarthy Tétrault LLP
The Patented Medicine Prices Review Board ("PMPRB" or the "Board") has published Draft Guidelines for public consultation, which are intended to operationalize the...
MLT Aikins LLP
December is in full swing, and many employers embrace the spirit of the season by hosting holiday parties for their employees
Smart & Biggar
On November 21, 2019, the Patented Medicine Prices Review Board (PMPRB) released draft Guidelines operationalizing the recent amendments to the Patented Medicines Regulations for consultation
Norton Rose Fulbright Canada LLP
This change comes into force January 1, 2020.
Bereskin & Parr LLP
It is important for innovative drug companies to take advantage of available exclusivities, to ensure that they can recoup investment from the costly drug...
Torys LLP
Last week, the Government of Canada signed an agreement to amend the United States-Mexico-Canada Agreement (USMCA).
Norton Rose Fulbright Canada LLP
The Ontario Ministry of Health and Long-Term Care (the Ministry) introduced changes to regulations (collectively, the Regulations) ...
Norton Rose Fulbright Canada LLP
The Patented Medicine Prices Review aboard (PMPRB) has extended the deadline for written submissions on new Draft Guidelines until January 31, 2020.
FREE News Alerts
Sign Up for our free News Alerts - All the latest articles on your chosen topics condensed into a free bi-weekly email.
Upcoming Events
Tools
Font Size:
Translation
Mondaq Social Media